Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of fluoxetine**, a selective serotonin reuptake inhibitor (SSRI), and **choline**, an essential nutrient and precursor of the neurotransmitter acetylcholine. There is no evidence of an FDA-approved or branded pharmaceutical product containing both fluoxetine and choline as a fixed combination, but research studies in animal models have investigated their synergistic effects on memory and neurobehavioral function under chronic mild stress. Fluoxetine increases synaptic serotonin by inhibiting its reuptake, commonly used to treat depression, OCD, and other psychiatric disorders[3][8]. Choline is a dietary nutrient necessary for the synthesis of acetylcholine, which plays roles in memory and cognitive function. Combined administration has been shown in rat models to improve memory retention and produce earlier cognitive effects compared to choline alone, suggesting possible synergy between serotonergic and cholinergic neurotransmitter systems[5]. No combination product with this formula is currently known to be marketed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoxetine + choline.